JP2021530238A5 - - Google Patents
Info
- Publication number
- JP2021530238A5 JP2021530238A5 JP2021503023A JP2021503023A JP2021530238A5 JP 2021530238 A5 JP2021530238 A5 JP 2021530238A5 JP 2021503023 A JP2021503023 A JP 2021503023A JP 2021503023 A JP2021503023 A JP 2021503023A JP 2021530238 A5 JP2021530238 A5 JP 2021530238A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- car
- cancer
- cytoplasmic signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700942P | 2018-07-20 | 2018-07-20 | |
| US62/700,942 | 2018-07-20 | ||
| PCT/US2019/042707 WO2020018973A1 (en) | 2018-07-20 | 2019-07-19 | Anti-lypd3 car t-cell therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530238A JP2021530238A (ja) | 2021-11-11 |
| JP2021530238A5 true JP2021530238A5 (https=) | 2022-07-26 |
Family
ID=69164634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503023A Pending JP2021530238A (ja) | 2018-07-20 | 2019-07-19 | がんの処置のための抗ｌｙｐｄ３ ｃａｒ ｔ細胞療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210309711A1 (https=) |
| EP (1) | EP3823992B1 (https=) |
| JP (1) | JP2021530238A (https=) |
| KR (1) | KR20210063319A (https=) |
| CN (1) | CN112955466A (https=) |
| AU (1) | AU2019305223A1 (https=) |
| CA (1) | CA3106967A1 (https=) |
| SG (1) | SG11202100571TA (https=) |
| WO (1) | WO2020018973A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| AU2010329904B2 (en) * | 2009-12-09 | 2015-07-09 | Bayer Pharma Aktiengesellschaft | Anti-C4.4a antibodies and uses thereof |
| US9790282B2 (en) * | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| CA3289997A1 (en) * | 2015-09-20 | 2026-03-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use |
| CN105132575B (zh) * | 2015-09-28 | 2020-03-27 | 固安博健生物技术有限公司 | 骨质疏松症的分子标志物及其应用 |
| GB201518136D0 (en) * | 2015-10-14 | 2015-11-25 | Glaxosmithkline Ip Dev Ltd | Novel chimeric antigen receptors |
| US11299708B2 (en) * | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| BR112018074453A2 (pt) * | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
| CN106119405B (zh) * | 2016-08-31 | 2019-11-12 | 广州万德基因医学科技有限公司 | 一种肺癌的预后标记物、使用该标记预测肺癌预后的方法及应用 |
| US20190269728A1 (en) * | 2018-03-02 | 2019-09-05 | Sixfold Bioscience Ltd. | Compositions for delivery of cargo to cells |
-
2019
- 2019-07-19 WO PCT/US2019/042707 patent/WO2020018973A1/en not_active Ceased
- 2019-07-19 JP JP2021503023A patent/JP2021530238A/ja active Pending
- 2019-07-19 EP EP19838801.9A patent/EP3823992B1/en not_active Revoked
- 2019-07-19 US US17/261,488 patent/US20210309711A1/en not_active Abandoned
- 2019-07-19 SG SG11202100571TA patent/SG11202100571TA/en unknown
- 2019-07-19 AU AU2019305223A patent/AU2019305223A1/en not_active Abandoned
- 2019-07-19 KR KR1020217004654A patent/KR20210063319A/ko not_active Ceased
- 2019-07-19 CA CA3106967A patent/CA3106967A1/en active Pending
- 2019-07-19 CN CN201980061125.6A patent/CN112955466A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018204209B2 (en) | Method and compositions for cellular immunotherapy | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| WO2021129559A1 (zh) | T细胞受体融合蛋白及其用途 | |
| JP2020517295A5 (https=) | ||
| EP4219693A1 (en) | Chimeric antigen receptor targeting cd7 and use thereof | |
| JP2020533958A5 (https=) | ||
| JP2022501043A5 (https=) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| FI3896091T3 (fi) | BCMA:han kohdentuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| CN113784980B (zh) | 人源化抗Claudin18.2嵌合抗原受体及其用途 | |
| US12522645B2 (en) | BCMA-targeted CAR-T cell therapy of multiple myeloma | |
| JP2020513829A5 (https=) | ||
| JP2019525956A5 (https=) | ||
| US20220184127A1 (en) | Humanized anti-dll3 chimeric antigen receptors and uses thereof | |
| JP2021500881A5 (https=) | ||
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof | |
| JP2022513682A5 (https=) | ||
| JP2022513372A5 (https=) | ||
| JP2024534471A5 (https=) | ||
| JP2024527557A5 (https=) | ||
| JP2023545907A (ja) | 新規共刺激ドメインを含むキメラ抗原受容体及びその使用 | |
| US20220162301A1 (en) | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof | |
| US20230242638A1 (en) | Chimeric antigen receptor targeting cldn18.2 and use thereof | |
| JP2021530238A5 (https=) | ||
| EP4663762A2 (en) | Immune rejection-resistant engineered cell |